BioSpace News Archive

Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.

The newly-created position is the result of rapid expansion at Paragon and its portfolio companies, which are developing novel medical treatments

Funds To Be Invested in Growth: New Products, New Markets and Talent

America’s trusted wellness partner is making changes that prevent almost 2 million pounds of carbon emissions annually, 25,000 pounds of plastic waste each year, and more for an eco-friendly future

Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that Daniel Soland has been appointed to its Board of Directors effective immediately.

One in six Canadian couples of childbearing age experience fertility challengesi, a number that has doubled since the 1980s.ii April 22 to 27 is Canadian Infertility Awareness Week, and EMD Serono, Canada is bringing attention to the far-reaching impact of infertility to encourage couples to educate themselves on reproductive health and family planning.

Oakrum Pharma, LLC announced that it has entered into an agreement with Biophore India Pharmaceuticals Pvt. to develop and manufacture two prescription generic pharmaceutical products that are intended to be commercialized in the U.S. under the Oakrum label.

The Pollack PR Marketing Group announced that Barco Uniforms has selected PPMG as its agency of record.

New license positions FSD to serve the growing medicinal use markets